4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report [Yahoo! Finance]
4D Molecular Therapeutics, Inc. (FDMT)
Company Research
Source: Yahoo! Finance
It was a moderately negative result overall - revenue fell 8.4% short of analyst estimates at US$21m, and statutory losses were in line with analyst expectations, at US$2.58 per share. Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. Readers will be glad to know we've aggregated the latest statutory forecasts to see whether the analysts have changed their mind on 4D Molecular Therapeutics after the latest results. See our latest analysis for 4D Molecular Therapeutics Taking into account the latest results, the current consensus, from the seven analysts covering 4D Molecular Therapeutics, is for revenues of US$4.26m in 2024. This implies a painful 79% reduction in 4D Molecular Therapeutics' revenue over the past 12 months. Losses are forecast to balloon 47% to US$2.97 per share. Before this earnings announcement, the analysts ha
Show less
Read more
Impact Snapshot
Event Time:
FDMT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FDMT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FDMT alerts
High impacting 4D Molecular Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
FDMT
News
- 4D Molecular Therapeutics, Inc. (FDMT) May Report Negative Earnings: Know the Trend Ahead of Q1 Release [Yahoo! Finance]Yahoo! Finance
- 4DMT Announces Presentations at ARVO 2024 Annual Meeting [Yahoo! Finance]Yahoo! Finance
- 4DMT Announces Presentations at ARVO 2024 Annual MeetingGlobeNewswire
- 4D Molecular Therapeutics: Catalysts With Pioneering Gene Therapy With Directed Evolution [Seeking Alpha]Seeking Alpha
- Ophthalmics Collaboration and Licensing Deals Collection, 2019-2024: Leading Deals by Value, Most Active Dealmakers, Benchmark Analysis, Financial Terms, and More [Yahoo! Finance]Yahoo! Finance
FDMT
Earnings
- 11/9/23 - Beat
FDMT
Sec Filings
- 4/18/24 - Form 4
- 4/10/24 - Form ARS
- 4/10/24 - Form DEFA14A
- FDMT's page on the SEC website